Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus Conversion in Heart Transplant Recipients
NCT04917718Phase 4Unknown
- Sponsor
- Loyola University Chicago
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in heart transplant rejection, sponsored by Loyola University Chicago. Primary endpoint: Urinary neutrophil gelatinase-associated lipocalin at 4 weeks. Status: unknown.
02
Drugs
tacrolimus
03
Conditions
heart transplant rejection
Beyond the preview
Go deeper on NCT04917718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917718.